IP Library › Patent Application 18097078
Patent Application
App. No. 18/097,078

MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/097,078
Abstract

The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.

Claims (14)

1 . A method for treating a patient having emphysema or COPD comprising administering a therapeutically effective amount of an EMAP II neutralizing antibody.

2 . The method according to claim 1 , further comprising generating the antibody by:

contacting the immune system of a mammal with a polypeptide consisting of SEQ ID NO: 12; and selecting a B-cell from the mammal;

wherein the B-cell produces antibodies that bind to endothelial monocyte activating protein II (EMAP II).

3 . The method according to claim 2 , wherein contacting the immune system of the mammal comprises immunizing the mammal.

4 . The method according to claim 2 , wherein selecting a B-cell from the mammal comprises isolating B-cells from the mammal, fusing the B-cells with myeloma cells thereby forming hybridomas, and selecting at least one hybridoma.

5 . The method according to claim 4 , wherein the at least one hybridoma is selected by testing hybridoma supernatant for binding of EMAP II by enzyme linked immunosuppression assay (ELISA).

6 . The method according to claim 1 , wherein the EMAP II neutralizing antibody comprises:

a heavy chain variable region, wherein said heavy chain variable region includes at least a portion of a first polypeptide according to SEQ. ID. NO. 2; and

a light chain variable region, wherein said light chain variable region includes at least a portion of a second polypeptide according to SEQ. ID. NO. 3, wherein said antibody is humanized and the humanized antibody binds to human EMAPII.

7 . The method according to claim 6 , wherein said first polypeptide has at least 99 percent homology to SEQ. ID. NO. 2, and said second polypeptide has at least 99 percent homology to SEQ. ID. NO. 3.

8 . The method according to claim 6 , wherein said first polypeptide has at least 95 percent identity to SEQ. ID. NO. 2 and said second polypeptide has at least 95 percent identity to SEQ. ID. NO. 3.

9 . The method according to claim 6 , wherein said first polypeptide has at least 99 percent identity to SEQ. ID. NO. 2 and said second polypeptide has at least 99 percent identity to SEQ. ID. NO. 3.

10 . The method according to claim 6 , wherein said first polypeptide is SEQ. ID. NO. 2 and said second polypeptide is SEQ. ID. NO. 3.